Ascorbic Acid Levels in MDS, AML, and CMML Patients

Van Andel Research Institute

Status: Completed

Conditions: CMML; AML; MDS; Myelodysplastic Syndromes; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia

Treatments: Other: Peripheral blood collection

Study type: Observational

Funder types: Other

Identifiers

NCT03526666

17022 (Registry Identifier)

Details and patient eligibility

About

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

Full description

It has previously been established that hematological cancer patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency from a cohort of patients in Copenhagen. In this study, the investigators aim to determine if those results are conserved in another population/geographical location.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients actively receiving treatment for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
• Patients diagnosed with AML, MDS, or CMML and are treatment naïve.
• Patients who are 18 years old or older.

Exclusion criteria

• Patients deemed as too ill to participate as determined by the clinical investigator.
• Non-English speaking patients
• Patients unable to provide informed consent.

Trial design

50 participants in 1 patient group

AML, MDS, and CMML patients

Description:

Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).

Treatment:

Other: Peripheral blood collection